Shots:

• The FDA has approved Nextstellis (3 mg- DRSP- and 14.2 mg- E4 tablets) for the prevention of pregnancy and is expected to be commercially available in Jun’2021
• The P-III study demonstrated the efficacy of Nextstellis across all subgroups through age- BMI and prior hormonal contraception use. The therapy is also associated with favorable bleeding control- including in cycle 1.
• Nextstellis is the 1st oral contraceptive pill containing E4 and is safe- effective- and well-tolerated in clinical trials with a desirable bleeding profile and minimal impact on triglycerides- cholesterol- glucose- as well as weight and endocrine markers

­ Ref: PRNewswire| Image: Mayne Pharma